UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 378

Sortiert nach

“Japan Diet” and Health—The Present and Future

Journal of Nutritional Science and Vitaminology, 2019/10/11, Vol.65(Supplement), pp.S29-S33

TERAMOTO, Tamio

2019

Link zum Volltext

Verfügbarkeit prüfen

Is “The Japan Diet” Cardioprotective?

Journal of Atherosclerosis and Thrombosis, 2017/04/01, Vol.24(4), pp.388-389

Teramoto, Tamio

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins　– ODYSSEY JAPAN Randomized Controlled Trial

Circulation Journal, 2016/08/25, Vol.80(9), pp.1980-1987

2016

Link zum Volltext

Verfügbarkeit prüfen

Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan —2012 Version

Journal of Atherosclerosis and Thrombosis, 2013, Vol.20(6), pp.517-523

2013

Link zum Volltext

Verfügbarkeit prüfen

Sitosterol prevents obesity-related chronic inflammation

Biochimica et biophysica acta. Molecular and cell biology of lipids, 2018-02, Vol.1863 (2), p.191-198

2018

Link zum Volltext

Verfügbarkeit prüfen

Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk: Primary Results From the Phase 2 YUKAWA Study

Circulation Journal, 2014, Vol.78(5), pp.1073-1082

2014

Link zum Volltext

Verfügbarkeit prüfen

Effects of Dietary Education Program for the Japan Diet on Cholesterol Efflux Capacity: A Randomized Controlled Trial

Journal of Atherosclerosis and Thrombosis, 2022/06/01, Vol.29(6), pp.881-893

2022

Link zum Volltext

Verfügbarkeit prüfen

Effects of Nutrition Education Program for the Japan Diet on Serum LDL-Cholesterol Concentration in Patients with Dyslipidemia: A Randomized Controlled Trial

Journal of Atherosclerosis and Thrombosis, 2021/10/01, Vol.28(10), pp.1035-1051

2021

Link zum Volltext

Verfügbarkeit prüfen

Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy

Journal of Atherosclerosis and Thrombosis, 2019/05/01, Vol.26(5), pp.408-431

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies)

The American journal of cardiology, 2016-07, Vol.118 (1), p.56-63

2016

Link zum Volltext

Verfügbarkeit prüfen

Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan

Journal of Atherosclerosis and Thrombosis, 2018/07/01, Vol.25(7), pp.580-592

2018

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic Criteria for Dyslipidemia: Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan—2012 Version

Journal of Atherosclerosis and Thrombosis, 2013, Vol.20(8), pp.655-660

2013

Link zum Volltext

Verfügbarkeit prüfen

Homogeneous Assays for LDL-C and HDL-C are Reliable in Both the Postprandial and Fasting State

Journal of Atherosclerosis and Thrombosis, 2017/06/01, Vol.24(6), pp.583-599

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan

Journal of Atherosclerosis and Thrombosis, 2019/03/01, Vol.26(3), pp.282-293

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive　― Results From a Randomized, Placebo-Controlled, Dose-Ranging Study

Circulation Journal, 2017/09/25, Vol.81(10), pp.1496-1505

2017

Link zum Volltext

Verfügbarkeit prüfen

One-Year Efficacy and Safety of Evolocumab in Japanese Patients　― A Pooled Analysis From the Open-Label Extension OSLER Studies

Circulation Journal, 2017/06/23, Vol.81(7), pp.1029-1035

2017

Link zum Volltext

Verfügbarkeit prüfen

Cholesterol 25-hydroxylation activity of CYP3A

Journal of lipid research, 2011-08, Vol.52 (8), p.1509-1516

2011

Link zum Volltext

Verfügbarkeit prüfen

Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan　― A Retrospective Database Analysis

Circulation Journal, 2018/05/25, Vol.82(6), pp.1605-1613

2018

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Food and Nutrient Intakes between Japanese Dyslipidemic Patients with and without Low-Density Lipoprotein Cholesterol Lowering Drug Therapy: A Cross-Sectional Study

Journal of Atherosclerosis and Thrombosis, 2020/07/01, Vol.27(7), pp.683-694

2020

Link zum Volltext

Verfügbarkeit prüfen

Effects of Nutrition Education Program for the Japan Diet on Serum Phospholipid Fatty Acid Compositions in Patients with Dyslipidemia: Re-analysis of Data from a Previous Randomized Controlled Trial

Journal of Atherosclerosis and Thrombosis, 2023/12/01, Vol.30(12), pp.1849-1869

2023

Link zum Volltext

Verfügbarkeit prüfen

Executive Summary of Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases for Japanese

Journal of Atherosclerosis and Thrombosis, 2007, Vol.14(2), pp.45-50

2007

Link zum Volltext

Verfügbarkeit prüfen

Dynamic prediction model and risk assessment chart for cardiovascular disease based on on-treatment blood pressure and baseline risk factors

Hypertension research, 2016-02, Vol.39 (2), p.113-118

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of alirocumab 150 mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON

Journal of cardiology, 2019-03, Vol.73 (3), p.218-227

2019

Link zum Volltext

Verfügbarkeit prüfen

Japanese Dietary Lifestyle and Cardiovascular Disease

Journal of Atherosclerosis and Thrombosis, 2011, Vol.18(9), pp.723-734

2011

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic Criteria for Dyslipidemia: Executive Summary of Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases for Japanese

Journal of Atherosclerosis and Thrombosis, 2007, Vol.14(4), pp.155-158

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 378

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(189)
Mit Volltextzugriff
(356)

Publikationsform

Artikel
(377)
Tagungsberichte
(1)

Sprache

Englisch
(322)
Japanisch
(157)

Erscheinungsjahr

n.n

Thema

Humans
(197)
Science & Technology
(193)
Life Sciences & Biomedicine
(189)
Male
(120)
Cardiovascular System & Cardiology
(109)
Female
(100)
Middle Aged
(86)
Peripheral Vascular Disease
(85)
Aged
(73)
Japan
(60)
Adult
(57)
Biological And Medical Sciences
(54)
Risk Factors
(53)
Internal Medicine
(46)
Cardiac & Cardiovascular Systems
(40)
Cardiology And Cardiovascular Medicine
(40)
Cholesterol, Ldl - Blood
(40)
Medical Sciences
(38)
Biochemistry
(32)
Japan - Epidemiology
(30)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

“Japan Diet” and Health—The Present and Future

Is “The Japan Diet” Cardioprotective?

Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins　– ODYSSEY JAPAN Randomized Controlled Trial

Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan —2012 Version

Sitosterol prevents obesity-related chronic inflammation

Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk: Primary Results From the Phase 2 YUKAWA Study

Effects of Dietary Education Program for the Japan Diet on Cholesterol Efflux Capacity: A Randomized Controlled Trial

Effects of Nutrition Education Program for the Japan Diet on Serum LDL-Cholesterol Concentration in Patients with Dyslipidemia: A Randomized Controlled Trial

Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy

Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies)

Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan

Diagnostic Criteria for Dyslipidemia: Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan—2012 Version

Homogeneous Assays for LDL-C and HDL-C are Reliable in Both the Postprandial and Fasting State

Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan

One-Year Efficacy and Safety of Evolocumab in Japanese Patients　― A Pooled Analysis From the Open-Label Extension OSLER Studies

Cholesterol 25-hydroxylation activity of CYP3A

Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan　― A Retrospective Database Analysis

Comparison of Food and Nutrient Intakes between Japanese Dyslipidemic Patients with and without Low-Density Lipoprotein Cholesterol Lowering Drug Therapy: A Cross-Sectional Study

Effects of Nutrition Education Program for the Japan Diet on Serum Phospholipid Fatty Acid Compositions in Patients with Dyslipidemia: Re-analysis of Data from a Previous Randomized Controlled Trial

Executive Summary of Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases for Japanese

Dynamic prediction model and risk assessment chart for cardiovascular disease based on on-treatment blood pressure and baseline risk factors

Efficacy and safety of alirocumab 150 mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON

Japanese Dietary Lifestyle and Cardiovascular Disease

Diagnostic Criteria for Dyslipidemia: Executive Summary of Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases for Japanese

Suchergebnisse filtern